The CRC first-line treatment involves a multimodal approach that usually comprises surgical resection and chemotherapy combined with monoclonal antibodies or proteins against vascular endothelial growth factor and epidermal growth factor receptor (EGFR) [15]. This evidence concerns the gene EGFR and colorectal carcinoma.